Skip to main content
OpenTrials
Completed

NCT Number: NCT04478877

Establishment and Characterization of Meningioma Patient-derived Organoids

In this study, meningioma organoids will be established from patients' tissues and the characterization of the organoid will be performed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Meningioma Central Nervous System Neoplasms Meningeal Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Nerve Tissue Neoplasms, Vascular Tissue Nervous System Diseases Nervous System Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Surgery, The Chinese University of Hong Kong

Hong Kong

About this study

Aims and Hypothesis to be tested:

The investigators hypothesized that the derived organoid should have a similar morphological and genetic mutation signatures to the patient primary tissue.

Study period: 1 year for patient recruitment and organoid generation from patient tumor

Study population: 30

Study samples:

Patient's meningioma tumor sample are collected from patients with surgical needs. Sample collected are used for organoid culture. Morphological and genetic characteristics will be compared between the patient tumor sample and the corresponding derived organoids

Primary outcome measures:

Whole exome sequencing data of patient tumor tissue and patients-derived organoids

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients (aged >18 years) with meningioma
  • Admission into Prince Wales hospitals neurosurgical services
  • Patients with surgical needs of meningioma removal

Exclusion criteria

  • Patients (or next-of-kin as appropriate) refuse to participate into the study

Treatment and study plan

Primary outcomes

  1. Whole exome sequencing data

    Time frame: 7 days

    DNA extracted from patient tumor tissue and patients-derived organoids will be perform whole exome sequencing for genetic characterization.

Secondary outcomes

  1. Immunostaining

    Time frame: 7 days

    H&E staining and meningioma markers immunostaining

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Jul 21, 2020
Registry last updated
Sep 7, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.